# Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

> **NCT00284089** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 88 (actual)

## Conditions studied

- Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00284089
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-03
- **Final completion:** 2009-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2011-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284089, "Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00284089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*